“Notwithstanding improvements in purification,
there is still the risk of blood-borne pathogens…
Every time a recombinant has come up
[against] a plasma [protein], whether human
or animal, it has taken over the market.”
—Bruce Carter, ZGEN CEO (from today’s CC)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”